Yuval Shaked
机构: Technion - Israel Institute of Technology
每年引用次数
引用次数
引用: 13,090
H-指数: 61
I10-指数 : 121
出版物: 241
STEM CELL TECHNOLOGY: EPIGENETICS, GENOMICS, PROTEOMICS, AND METABONOMICS
LIAT BENAYOUN , SVETLANA GINGIS-VELITSKI , TALI VOLOSHIN , EHUD SEGAL
460 Antiangiogenic drug alterations of the tumor microenvironment which can impact chemotherapy efficacy
R. Kerbel , J. Ebos , Y. Shaked
Ejc Supplements 8 ( 7) 149
2010
ATF3-dependent cross-talk between cardiomyocytes and macrophages promotes cardiac maladaptive remodeling
L. Koren , D. Alishekevitz , O. Elhanani , A. Nevelsky
International Journal of Cardiology 198 232 -240
25
2015
1314P Blood-based proteomic biomarkers for predicting response to immunotherapy in non-small cell lung cancer
Y. Shaked , I. Kamer , M. Harel , C. Lahav
Annals of Oncology 31
2020
1MO A proteomics-based platform for predicting response to immunotherapy and personalising treatment plans
Y. Shaked , C. Lahav , M. Harel , E. Jacob
Annals of Oncology 31
2020
Differential Therapeutic Effects of Anti–VEGF-A Antibody in Different Tumor Models: Implications for Choosing Appropriate Tumor Models for Drug Testing
D. Alishekevitz , R. Bril , D. Loven , V. Miller
Molecular Cancer Therapeutics 13 ( 1) 202 -213
12
2014
Palliation of relapsed aggressive histology NHL with high-dose celecoxib and 'metronomic' low-dose cyclophosphamide.
R. Buckstein , M. Crump , Y. Shaked , C. Foden
Journal of Clinical Oncology 22 3016 -3016
6
2004
Altered metabolism of cyclophosphamide given in a low-dose metronomic manner does not account for eventual resistance
U. Emmenegger , Y. Shaked , G. Bocci , I. Spasojevic
Journal of Clinical Oncology 23 3185 -3185
2005
Mechanisms of resistance to low-dose metronomic cyclophosphamide
U. Emmenegger , L. Chen , Y. Shaked , G. Francia
Journal of Clinical Oncology 24 13079 -13079
2006
S7 Combination cyclophosphamide — UFT metronomic low-dose chemotherapy for the treatment of metastatic breast cancer: A preclinical analysis
R. Mu oz , Y. Shaked , U. Emmenegger , S. Man
The Breast 14
11
2005
Predictive potential of angiogenic growth factors and circulating endothelial cells in breast cancer patients receiving metronomic chemotherapy plus bevacizumab
A. Calleri , A. Bono , V. Bagnardi , J. Quarna
Clinical Cancer Research 15 ( 24) 7652 -7657
94
2009
A phase I study of bevacizumab in children with refractory solid tumors: A Children’s Oncology Group study
J. L. Glade Bender , P. C. Adamson , S. Baruchel , Y. Shaked
Journal of Clinical Oncology 24 ( 18_suppl) 9017 -9017
4
2006
Preliminary results of a phase II study of continuous low dose metronomic (LDM) cyclophosphamide (CTX) and celecoxib (CEL) for asymptomatic hormone refractory prostate cancer (HRPC) with assessment of anti-angiogenic biomarkers
S. R. Berry , Y. Ko , U. Emmenegger , Y. Shaked
Journal of Clinical Oncology 25 14046 -14046
1
2007
Endothelial progenitor cells are cellular hubs essential for neoangiogenesis of certain aggressive adenocarcinomas and metastatic transition but not adenomas.
R. S. Kerbel , R. Benezra , D. C. Lyden , K. Hattori
Proceedings of the National Academy of Sciences of the United States of America 105 ( 34)
47
2008
High Dose Celecoxib and Metronomic ‘Low-Dose’ Cyclophosphamide Is Effective Therapy in Patients with Relapsed and Refractory Aggressive Histology NHL.
Rena Buckstein , M. Crump , Y. Shaked , D. Spaner
Blood 104 ( 11) 4622 -4622
1
2004
Method of treating cancer with compositions comprising IL-31
Fremder Ella , Aronheim Ami , Shaked Yuval
2020
Correction: Glioma Tumor Stem-Like Cells Promote Tumor Angiogenesis and Vasculogenesis via Vascular Endothelial Growth Factor and Stromal-Derived Factor 1
C FOLKINS , Y SHAKED , S MAN , T TANG
Cancer research 69 ( 20)
2009
Dual effects of different anti-angiogenic therapies over circulating endothelial progenitors and mature cells
Angelica Calleri , Cristina Rabascio , Alice Agliano , Ines Martin Padura
Cancer Research 66 939 -939
2006
Methods for enhancing the efficacy of vascular disrupting agents
Yuval Shaked , Robert Kerbel
7
2008
Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells.
Silvia Monestiroli , Francesco Bertolini , Patrizia Mancuso , Yuval Shaked
Cancer Research 63 ( 15) 4342 -4346
611
2003